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Epidemiological studies show a reciprocal inverse association between cancer and
Alzheimer’s disease (AD). The common mechanistic theory for this effect posits that cells
have an innate tendency toward apoptotic or survival pathways, translating to increased
risk for either neurodegeneration or cancer. However, it has been shown that cancer
patients experience cognitive dysfunction pre- and post-treatment as well as alterations
in cerebral gray matter density (GMD) on MRI. To further investigate these issues, we
analyzed the association between cancer history (CA±) and age of AD onset, and the
relationship between GMD and CA± status across diagnostic groups in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) cohort study. Data was analyzed from 1609
participants with information on baseline cancer history and AD diagnosis, age of AD
onset, and baseline MRI scans. Participants were CA+ (N = 503) and CA− (N = 1106)
diagnosed with AD, mild cognitive impairment (MCI), significant memory concerns (SMC),
and cognitively normal older adults. As in previous studies, CA+ was inversely associated
with AD at baseline (P = 0.025); interestingly, this effect appears to be driven by non-
melanoma skin cancer (NMSC), the largest cancer category in this study (P = 0.001). CA+
was also associated with later age of AD onset (P < 0.001), independent of apolipoprotein
E (APOE) ε4 allele status, and individuals with two prior cancers had later mean age
of AD onset than those with one or no prior cancer (P < 0.001), suggesting an additive
effect. Voxel-based morphometric analysis of GMD showed CA+ had lower GMD in the
right superior frontal gyrus compared to CA− across diagnostic groups (Pcrit < 0.001,
uncorrected); this cluster of lower GMD appeared to be driven by history of invasive cancer
types, rather than skin cancer. Thus, while cancer history is associated with a measurable
delay in AD onset independent of APOE ε4, the underlying mechanism does not appear
to be cancer-related preservation of GMD.
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INTRODUCTION
Multiple epidemiological studies have identified a significant
inverse association between cancer and Alzheimer’s disease (AD),
primarily in white non-Hispanic cohorts (Tirumalasetti et al.,
1991; Desouky, 1992; Yamada et al., 1999; Roe et al., 2005,
2010; Driver et al., 2012; Realmuto et al., 2012; Musicco et al.,
2013). These studies provide convincing evidence that cancer
history reduces the risk of AD in the white non-Hispanic pop-
ulation, with effect sizes ranging from 0.4 to greater than 0.6
(Roe et al., 2005; Driver et al., 2012; Musicco et al., 2013; Roe
and Behrens, 2013; Catala-Lopez et al., 2014). Supporting the
validity and specificity of this effect, a study by Roe et al. (2010)
found the inverse association of cancer specific to AD as com-
pared to vascular dementia. Another study by Musicco et al.
(2013) identified the inverse association of cancer and AD in a
very large population-based Italian sample accounting for physi-
cian and survival bias. This study of invasive cancer types found
reduced relative risk of AD in subpopulations of breast, lung,
bladder, prostate, and colorectal cancer survivors, though only
the colorectal cancer subpopulation risk reduction was statisti-
cally significant. Interestingly, the cancers represented in most of
these study populations were highly heterogeneous, suggesting
that rather than specific cancer effects, such as estrogen depri-
vation in breast cancer, the inverse association between cancer
and AD is likely due to strong underlying biological mechanisms.
Identification of these biological mechanisms may provide direc-
tion to future therapeutic efforts, particularly for AD, as there is
currently a significant lack of effective treatments for this disease.
www.frontiersin.org October 2014 | Volume 5 | Article 423 | 1
Nudelman et al. Cancer history and Alzheimer’s disease
There are many proposed mechanisms that may explain the
inverse association of AD and cancer (Behrens et al., 2009;
Holohan et al., 2012; Driver, 2014); a common theory posits that
it is primarily driven by genetic predisposition and molecular
mechanisms either promoting or suppressing metabolic survival
or apoptotic cellular pathways. This metabolic survival theory is
supported by a recent paper by Ibanez et al. (2014), that identified
genes differentially expressed in AD and several types of cancer
concentrated in metabolic and genetic information processing
pathways essential for cell survival and apoptotic regulation. As
regional neurodegeneration, including loss of gray matter den-
sity (GMD), is a hallmark of AD, it was hypothesized that if
this theory is correct, older individuals with a history of can-
cer (CA+) would exhibit preserved GMD compared to those
without cancer history (CA−), and that lower GMD in CA−
would be related to earlier age of AD onset in contrast to CA+
individuals.
However, cognitive and neuroimaging studies of breast cancer
patients provide convincing evidence that CA+ survivors treated
with chemotherapy have decreased GMD, more memory con-
cerns, and worse neuropsychological test performance than CA−,
up to 20 years post-treatment (Ahles et al., 2002; McDonald et al.,
2010; Koppelmans et al., 2012a,b; McDonald et al., 2013; Stouten-
Kemperman et al., 2014). There is some evidence to support the
negative impact of hormone therapies on perceived and objec-
tive cognitive function (Schilder et al., 2009, 2010a; Boele et al.,
2014), and that radiotherapy may also be associated with cogni-
tive dysfunction (Shibayama et al., 2014). Furthermore, although
the focus of this research to date has been on the effects of can-
cer treatments on brain structure and function, several studies
of breast cancer patients have also found pre-treatment deficits
in neuropsychological performance and brain activation, sug-
gesting that CA+ may be associated with cognitive dysfunction,
independent of treatment effects (Cimprich et al., 2010; Schilder
et al., 2010b; Scherling et al., 2011). Finally, as previously reviewed
(Holohan et al., 2013), there have been several imaging studies in
heterogeneous cancer populations which have shown differences
in brain activation compared to CA−, suggesting that these effects
are not limited to breast cancer (Tashiro et al., 1999, 2000, 2001;
Golan et al., 2009; Benveniste et al., 2012). It has been suggested
based on this evidence that cancer and treatment-related changes
may be responsible for an accelerated aging process, particularly
in subgroups of more vulnerable patients (Ahles et al., 2012).
These results and line of reasoning predict that CA+ should
experience greater cognitive dysfunction and neurodegeneration
compared to CA−, whichmay actually worsen over time for some
individuals.
This growing body of cancer and cognition literature appears
to be in conflict with the metabolic survival theory posited to
underlie the inverse association of cancer and AD. To investi-
gate this apparent contradiction, this cohort study utilized the
Alzheimer’s Disease Neuroimaging Initiative dataset, comprising
cognitively normal older adults (CN), participants with signif-
icant memory concern (SMC) in the absence of psychometric
evidence of cognitive decline, older adults diagnosed with early
and late mild cognitive impairment (MCI), and patients with
mild clinical AD, to investigate the effect of cancer history on AD-
related neurodegeneration. We hypothesized that our findings
in this independent sample would be consistent with previ-
ous research showing an inverse relationship of cancer and AD.
However, also based on previous research, we expected to observe
cognitive dysfunction and brain structural changes in cancer
patients.
MATERIALS AND METHODS
ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI)
Data used in the preparation of this article were obtained from
the ADNI database (adni.loni.usc.edu). ADNI was launched in
2004 as a collaboration including the National Institute on
Aging (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration
(FDA), pharmaceutical companies, and non-profit organizations.
It was framed as a multi-year, public-private partnership, headed
by Principal Investigator Michael W. Weiner, MD, VA Medical
Center and UCSF. Many co-investigators from over 50 sites across
the United States (U.S.) and Canada have contributed to this
longitudinal study, recruiting more than 1700 participants (aged
50–90) in three phases, ADNI-1, ADNI-GO, and ADNI-2.
The ADNI study design is described briefly as follows.
Participants were collected from across North American in
three phases, ADNI-1, ADNI-GO, and ADNI-2; target partic-
ipant numbers are listed in Table 1. This is not a population
study, as the focus was on recruiting participants with spe-
cific AD-spectrum diagnoses. ADNI-GO and ADNI-2 added
recruitment of early (EMCI) and late MCI (LMCI) to study
the full spectrum of AD progression; these participants were all
counted as MCI for the purposes of this analysis. As seen in
Table 1, while ADNI-1 collected MRI, fluorodeoxyglucose (FDG)
positron emission tomography (PET), and Pittsburgh compound
B (PiB) PET, later phases of ADNI collected several additional
Table 1 | ADNI study design.
Participants* Data collection
CN EMCI MCI LMCI AD MRI fMRIa DTIb FDG AV45c PiB Biosd
ADNI-1 200 – 400 – 200 X X X X
ADNI-GO ↓ 200 ↓ – – X X X X X X
ADNI-2 150 150 ↓ 150 200 X X X X X X
afMRI, functional MRI; bDTI, diffusion tensor imaging; cAV45, florbetapir PET amyloid imaging; d Bios, biological samples. *Numbers are study targets, not final
statistics. Arrows indicate that study participants continued longitudinally in later phases of ADNI.
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types of neuroimaging data. All data phases collected neuropsy-
chological and self-reported cognitive data, biological samples
such as blood for genetic analysis, and demographic and medi-
cal history data. Longitudinal protocols included data collection
for each participant every 6 months for the first 2 years, and every
12 months after this point. Further information on ADNI study
design, protocols, diagnostic criteria, and all measurements uti-
lized in this analysis can be found at http://adni.loni.usc.edu/ and
in previous reports (Jack et al., 2010; Jagust et al., 2010; Petersen
et al., 2010; Saykin et al., 2010; Trojanowski et al., 2010; Weiner
et al., 2010, 2012, 2013). Institutional Review Board approval was
obtained by each ADNI site, and informed consent was obtained
from each study participant or authorized representative.
PARTICIPANTS
Self-reported demographic information for all three ADNI phases
included baseline age, education, sex, race, ethnicity, and hand-
edness. These factors have all been previously associated with AD
diagnosis (Farrer et al., 1997; Fitten et al., 2001; Shadlen et al.,
2006; Meng and D’arcy, 2012; Salmon et al., 2013; Yang et al.,
2014), and as such were considered potential confounders; par-
ticipants were excluded from this analysis if they were missing
any of this information. Additionally, participants were geno-
typed for apolipoprotein E (APOE) ε2/3/4 alleles as described
previously; since APOE ε4 is the major known genetic risk factor
for late-onset AD and a potential confounder, participants were
also excluded if they were missing this data (Saykin et al., 2010;
Risacher et al., 2013). All participants included in this analy-
sis met ADNI inclusion and exclusion criteria, which have been
described previously, and can be found at http://www.adni-info.
org/ (Weiner et al., 2010). A general exclusion rule, as stated in the
Procedures Manual, was that a history of any cancer other than
non-melanoma skin cancer (NMSC) within 5 years of screening
was exclusionary. However, the manual also states that exceptions
may be made on a case by case basis. Review of qualitative med-
ical data indicated that there were exceptions made to this rule,
primarily for individuals with prostate cancer, but also for indi-
viduals with other types of cancer which had been successfully
treated and were in remission at the time of study enrollment.
Participants were categorized at baseline as CN, SMC, MCI, or
mild AD. More information on measures utilized in diagnosis is
available on the ADNI website; basic diagnostic criteria are also
briefly summarized as follows. Criteria considered include: sub-
ject, informant, and clinician report of memory concerns, mem-
ory function documented by neuropsychological testing scores
compared to education-adjusted cutoffs on the Logical Memory
II subscale (Delayed Paragraph Recall, Paragraph A only) from
the Wechsler Memory Scale - Revised (maximum score = 25),
Mini-Mental State Exam score out of 30 (Folstein et al., 1975),
Clinical Dementia Rating (CDR, range 0–1) (Morris, 1993), and
qualitative assessment by a physician of cognitive function and
functional performance, guided by the NINCDS/ADRDA crite-
ria (McKhann et al., 1984). CN participants show no signs of
depression, memory complaints, MCI, or dementia; neuropsy-
chological memory testing is within the normal range (>8 for
16 or more years of education, >4 for 8–15 years of education,
or >2 for 0–7 years of education), they have a Mini-Mental
State Exam score between 24 and 30, and have a CDR of 0.
SMC individuals exhibit some forgetfulness; however, their infor-
mant does not indicate that they are consistently forgetful or
experiencing progressive memory impairment. They score within
the normal cognitive range for memory function, have MMSEs
between 24 and 30, and have a CDR of 0. MCI individu-
als report subject memory concerns, show abnormal memory
function documented by neuropsychological testing (<9 for 16
or more years of education, <5 for 8–15 years of education,
or <3 for 0–7 years of education), have MMSEs between 24
and 30, and have a CDR of 0.5; however, their general cogni-
tion and functional performance are sufficiently preserved such
that a diagnosis of AD cannot be made by the site physician
at the time of the visit. Finally, individuals with AD exhibit
memory concerns, abnormal memory function documented by
neuropsychological testing, have MMSEs between 20 and 26,
have CDRs of 0.5 or 1.0, and meet NINCDS/ADRDA criteria for
probable AD.
As described in Saykin et al. (2010), APOE was genotyped
using the two single nucleotide polymorphisms (SNPs) rs429358
and rs7412. A 3mL sample of blood was taken in ethylenedi-
aminetetraacetic acid (EDTA)-containing vacutainer tubes from
all participants. Genomic DNA was extracted at Cogenics (now
Beckman Coulter Genomics) utilizing the QIAamp DNA Blood
Maxi Kit (Qiagen, Inc., Valencia, CA), following the manufac-
turer’s protocol. Polymerase chain reactions were used to amplify
participant DNA, followed by HhaI restriction enzyme digestion,
resolution on 4% Metaphor Gel, and visualization by ethidium
bromide staining.
Baseline age, education, sex, race, and ethnicity (white non-
Hispanic vs. all other reported races/ethnicities), handedness,
and APOE ε4 status (0 ε4 alleles vs. at least 1 ε4 allele) were
all analyzed for significant differences between cancer and AD
diagnostic groups using Pearson Chi-Square and ANOVA meth-
ods in SPSS 21 (SPSS Statistics 21, IBM Corporation, Somers,
NY), to determine whether these potential confounders should
be included in further analyses.
Qualitative and quantitative self-reported medical history data
was also obtained for all ADNI study participants. For the pur-
poses of this analysis, all qualitative medical history data was
manually curated to obtain a complete, more accurate account
of each individual’s cancer history than was available based on
quantitative data. All cancer types were considered for this analy-
sis, including NMSC. Medical information regarding cancer was
broken down into pre-baseline cancer history (yes, 1, CA+; no,
0, CA−), as well as a count of prior cancer incidences. Reports
of multiple NMSC were only counted as one cancer incidence,
given the benign, prevalent nature of this cancer, as well as the
lower quality of documentation regarding exact number of inci-
dences. Cancer types were recorded and divided into 14 categories
for analysis. Cancer types with only one incidence that did not fit
any other categories were categorized as “Other”; notably, there
were only seven of these cancer types, showing that the other 13
categories represent the majority of observed cancer. Chi-square
analysis of cancer categories by AD diagnostic group was per-
formed to test for potential sample bias. Post-baseline cancer
incidents were not utilized in this study due to the small number
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(43 total), which were distributed evenly between groups (chi
square χ2 = 4.054, p = 0.256).
MRI ACQUISITION
MRI scans acquisition varied as part of the three ADNI initia-
tives. ADNI-1 participants’ structural MRI baseline scans were
acquired using 1.5 Tesla field strength; ADNI-2 and ADNI-GO
both utilized 3 Tesla field strength. All available baseline struc-
tural MRI scans were downloaded from LONI (http://adni.loni.
usc.edu/) for included ADNI participants. Scans were corrected
prior to download as previously described (Jack et al., 2008,
2010).
COMORBIDITY ASSOCIATION ANALYSIS
Cancer history (CA+/CA−; prior to baseline) was analyzed for
association with baseline AD diagnosis (four groups) using the
Chi-Square test. Post-hoc analysis was also performed analyzing
three types of cancer history, NMSC, prostate cancer, and breast
cancer.
Following these results, survival analysis was performed to
analyze age of AD onset by cancer history. A time variable was
created utilizing age of AD onset for participants diagnosed with
AD before or during the study, and age at most current visit for
all other study participants. To address potential sources of bias,
this time variable was pre-adjusted for the following confounding
variables identified in the demographic analysis: sex, education,
handedness, race/ethnicity, and APOE ε4 allele status. A censor
variable was used to denote AD (1) and non-AD (0) partici-
pants. Cox regression and Kaplan-Meier survival analyses were
conducted utilizing these time and censor variables with CA±
status as the factor of interest. Median age of AD onset and 95%
confidence intervals (CI) were estimated using the Kaplan-Meier
method, and Cox regression forwardWald tests were used to gen-
erate Chi-square statistics, significance, and odds ratios (OR), as
well as graphical representations. A similar analysis using num-
ber of prior cancer incidences as the factor of interest was also
conducted. Finally, post-hoc analysis investigated the association
of the two most common cancer types, NMSC and prostate can-
cer, with pre-adjusted age of AD onset, using similar methods.
Analyses were conducted using SPSS 21.
Of the 1609 included study participants, 257 individuals con-
verted to AD post-baseline, bringing the AD group sizes for this
analysis to 160 CA+ AD and 410 CA− AD (totalN = 570), while
CA+ (N = 343) and CA− (N = 696) included in other diag-
nostic groups were censored. For the AD cancer history number
of incidences analysis, 23 individuals out of the total 570 had a
history of two cancers; no individuals with AD at baseline or indi-
viduals who converted to AD during the study had more than two
prior cancers.
IMAGE ANALYSIS
Scans were processed for voxel-based morphometry (VBM)
analyses in Statistical Parametric Mapping 8 (SPM8; Wellcome
Department of Cognitive Neuroscience, London, UK), using an
updated version of procedures described in previous reports
(Ashburner and Friston, 2000; Risacher et al., 2009, 2010, 2013).
The majority of participants had at least two scans from the
baseline visit; the first acquired scan of acceptable quality was
used. Briefly, scans were co-registered to a T1-weighted template,
segmented into gray matter, white matter, and CSF compart-
ments with bias correction, and normalized unmodulated to
Montreal Neurologic Institute (MNI) space as 1 × 1 × 1mm vox-
els. Smoothing was performed with an 8mm Gaussian kernel.
Extensive quality control was performed on all scans. 1609 ADNI
participants had all baseline demographic and medical data and
baseline scans that passed all quality control measures.
VBM analysis of GMD was performed in SPM8 to analyze
differences between AD/cancer groups. The 1609 included par-
ticipants were divided into eight groups based on AD diagnostic
group and CA± status, and baseline corrected scans were ana-
lyzed for group differences using a full factorial model, covary-
ing for potential confounding variables including study phase,
field strength (1.5 Tesla or 3 Tesla), total intracranial volume
(ICV), age, sex, education, handedness, race/ethnicity (white
non-Hispanic vs. all else), and APOE ε4 allele status. The SPM8
standard gray matter explicit mask was included in the model.
Initial results suggested that this mask may not exclude some
differences in white matter regions within the brain stem and
cerebellum, likely noise caused by atrophy in the AD group; the
SPM8 white matter exclusive mask was used to confirm that these
changes occurred in white matter.
Weighted contrast vectors were entered for each group in the
design matrix to test hypotheses regarding differences in neu-
rodegeneration across the eight AD/cancer groups. AD and MCI
groups were expected to show greater neurodegeneration across
large regions of the brain compared to other groups; to confirm
this, a linear model of less GMD for each group further along the
AD spectrum was applied (−2 for AD CA+/CA−, −1 for MCI
CA+/CA−, 1 for SMC CA+/CA−, and 2 for CN CA+/CA−).
The critical significance voxel-wise threshold (Pcrit) was set to
0.001 uncorrected, and the minimum cluster extent (k) for this
contrast was set to 0; given the extensive GMD loss observed in
AD and MCI, there was no correction for cluster size included.
To test the hypothesis that cancer history was inversely associ-
ated with neurodegeneration, the model included weights of +1
for each CA+ group and −1 for each CA− group. CA+/CA−
changes within each AD diagnostic group were considered in a
similar fashion, and AD CA+/CA−were also contrasted with CN
CA+/CA−. For each hypothesis, inverse models were also tested
to confirm the specificity of the findings. The critical significance
voxel-wise threshold (Pcrit) was set to 0.001 uncorrected, with
a minimum cluster extent (k) of P ≤ 0.1 uncorrected voxels for
these contrasts.
For the significant cluster identified in voxel-wise model of
CA+ lower GMD across diagnostic groups, mean cluster GMD
value was extracted for all individuals using MarsBar in SPM8
(Brett et al., 2002). These values were analyzed and graphed
in SPSS 21 to further investigate diagnostic group differences
in GMD change. One outlier from the MCI CA− group with
GMD greater than three standard deviations from the mean
was excluded. These values were also analyzed with the General
Linear Model Univariate ANOVA method, testing for associa-
tion with types of cancer, covarying for demographic variables
previously listed as well as baseline AD diagnostic group. Types
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of cancer tested included the four largest categories (NMSC,
prostate, breast, and melanoma), as well as a category including
all cancer types except NMSC. To test specifically whether non-
malignant, non-invasive NMSC was associated with this effect,
this cancer category was modified for this analysis to exclude indi-
viduals who had also had any other type of cancer (57 individuals
excluded from 246).
RESULTS
DEMOGRAPHIC ANALYSIS
The 1609 individuals analyzed in this study were obtained as fol-
lows. 1818 individuals had ADNI medical history files. Of these,
1780 also had pertinent demographic information (as listed in
Table 2). Out of these individuals, 1609 had quality-controlled
MRI scans available for analysis.
Demographic and disease characteristics of the cohort
are summarized in Table 2. Age, sex, education, handedness,
race/ethnicity, and APOE ε4 allele status were all significantly
different between AD/cancer groups. There was a significant,
expected association between cancer history and smoking (Chi-
square χ2 = 4.2, P = 0.024), but smoking only showed a trend
for association with AD diagnostic groups (χ2 = 6.8, P = 0.078),
with a higher portion of SMC individuals reporting they had ever
smoked. Since a higher portion of individuals with cancer were
also SMC, the trend for smoking association is likely confounded
by cancer history. Given this result, smoking was not included as
a covariate in subsequent analyses.
Given that previous studies used highly heterogeneous can-
cer populations, the distribution of cancer types in ADNI was
further examined. Out of the 1609 individuals utilized in this
analysis, there were 421 individuals with a history of one prior
cancer, and 82 individuals with a history of multiple cancers,
yielding 593 total recorded cancer incidences. Cancer types were
classified into 14 categories, as shown in Figure 1 and Table 3.
Although there are some differences in cancer distribution among
groups, overall, cancer category percentages were not significantly
different between diagnostic groups (Chi-square χ2 = 31.2, P =
0.8). Subsequent analyses investigating the inverse association of
cancer and AD were therefore performed using all types of cancer
unless otherwise stated.
In addition to baseline data collection, participants were also
assessed at a number of follow-up visits, including visits at
month(M)6, M12, M18, M24, M36, M48, M60, M72, M84, and
M96. Though all other analyses concern data collected at baseline,
longitudinal information on participant age and diagnosis at
FIGURE 1 | Categorized cancer types count out of 593 total incidences.
14 categories were created from the original 40 cancer types; most are
self-explanatory, such as all types of cancer related to female organs aside
from breast categorized as “Female Other.” The “Other” category
contained seven types of cancer with one reported case, which did not fit
into any other category. GI, gastrointestinal cancer (including colorectal
cancer); NMSC, non-melanoma skin cancer.
Table 2 | ADNI total cohort demographics (N = 1609).
CA+ CN CA− CN CA+ SMC CA− SMC CA+MCI CA−MCI CA+ AD CA− AD Pa
ADNI-1 75 135 0 0 108 258 45 133
ADNI-GO 0 1 0 0 50 78 0 0
ADNI-2 54 126 34 44 99 234 38 97
ADNI Total 129 262 34 44 257 570 83 230 <0.001*
Age 76 (5.4) 74 (5.9) 73 (6.4) 71 (4.8) 75 (6.9) 72 (7.8) 77 (7.7) 74 (7.8) <0.001+
Education 15 (3.3) 15 (2.9) 16 (2.8) 16 (2.8) 17 (2.5) 17 (2.3) 17 (2.5) 16 (2.7) <0.001+
% Male 68% 48% 68% 55% 53% 48% 61% 45% <0.001*
% R-Hand 97% 89% 88% 87% 88% 91% 92% 95% 0.037*
% White, NH 94% 81% 94% 87% 95% 88% 94% 88% <0.001*
% APOE ε4+ 29% 28% 38% 27% 49% 49% 60% 68% <0.001*
% Ever smoked 49% 35% 59% 50% 39% 40% 45% 36% 0.021*
All included values collected at baseline; participants from ADNI-1 who continued in ADNI-GO or 2 are reported as ADNI-1. Age and education values in years are
mean (standard deviation). % R-Hand, % right handed; % White NH, % white non-Hispanic individuals; % APOE ε4+, % individuals with at least one APOE ε4
allele.
aP-value for Pearson Chi-Square(*) or ANOVA(+) with dependent variables listed and independent variable for treatment group/cancer history (eight groups, as
shown).
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Table 3 | Cancer categories count and percentage by diagnostic
group.
Cancer CN SMC MCI AD Total
category
NMSC 74 (46.0%) 19 (48.7%) 123 (40.6%) 30 (33.3%) 246 (41.5%)
Prostate 29 (18.0%) 4 (10.3%) 73 (24.1%) 24 (26.7%) 130 (21.9%)
Breast 19 (11.8%) 5 (12.8%) 25 (8.3%) 9 (10.0%) 58 (9.8%)
Melanoma 10 (6.2%) 5 (12.8%) 16 (5.3%) 7 (7.8%) 38 (6.4%)
GI 9 (5.6%) 2 (5.1%) 22 (7.3%) 4 (4.4%) 37 (6.2%)
Female other 8 (5.0%) 1 (2.6%) 8 (2.6%) 6 (6.7%) 23 (3.9%)
Glandular 3 (1.9%) 2 (5.1%) 12 (4.0%) 3 (3.3%) 20 (3.4%)
Bladder 2 (1.2%) 1 (2.6%) 4 (1.3%) 3 (3.3%) 10 (1.7%)
Renal 1 (0.6%) 0 (0.0%) 4 (1.3%) 2 (2.2%) 7 (1.2%)
Lymphoma 2 (1.2%) 0 (0.0%) 3 (1.0%) 1 (1.1%) 6 (1.0%)
Male other 1 (0.6%) 0 (0.0%) 3 (1.0%) 0 (0.0%) 4 (0.7%)
Oral 1 (0.6%) 0 (0.0%) 3 (1.0%) 0 (0.0%) 4 (0.7%)
Leukemia 1 (0.6%) 0 (0.0%) 1 (0.3%) 1 (1.1%) 5 (0.5%)
Other 1 (0.6%) 0 (0.0%) 6 (2.0%) 0 (0.0%) 7 (1.2%)
Total 161 (100%) 39 (100%) 303 (100%) 90 (100%) 593 (100%)
Values are expressed as count (percentage of cancer category out of total
within each diagnostic group). “Other” category consists of cancer types that
do not fit within another category; these included one each of the following can-
cer types: bone, chondrosarcoma, gallbladder, lung, meningioma, liposarcoma,
and a foot tumor of unspecified origin. NMSC, non-melanoma skin cancer; GI,
gastrointestinal.
most current (latest) visit was downloaded on July 29, 2014 from
the ADNI website (http://adni.loni.usc.edu/) for use in age of
AD onset analyses discussed below. The numbers of participants
at each most current visit were as follows: baseline (N = 115),
M6 (N = 132), M12 (N = 292), M18 (N = 25), M24 (N = 533),
M36 (N = 223), M48 (N = 49), M60 (N = 26), M72 (N = 52),
M84 (N = 101), and M96 (N = 61). Because ADNI-GO and
ADNI-2 are newer initiatives, participants in these phases of
the study do not yet have visits beyond M48; data collection
is ongoing. Of the 115 individuals with no visits beyond base-
line, most participants withdrew voluntarily after this visit, for
reasons including scheduling, discomfort, or unwillingness to
comply with protocols (particularly lumbar puncture), or part-
ner/caregiver burden. There were 12 participants for whom there
was no available data on reason for loss to follow-up, and an addi-
tional five participants who could not be contacted after the initial
visit. Among the remaining participants with baseline data, there
were four participant deaths (three AD and one MCI), and seven
participants who withdrew due to stated medical issues (two CN,
four MCI, and one AD). Given the small number of participant
withdrawals attributable to medical issues and death, it is unlikely
that this is a source of bias for the longitudinal data analysis.
AD AND CANCER INVERSE ASSOCIATION
Chi-Square analysis indicated that CA+ was significantly associ-
ated with AD diagnostic group at baseline (χ2 = 9.4, P = 0.025).
As seen in Figure 2 and Table 4, fewer study participants with
AD are CA+ compared to other diagnostic groups. Interestingly,
individuals with SMC are more evenly divided between CA+ and
CA− than other groups.
FIGURE 2 | Percent of individuals with cancer history (CA+) per
diagnostic group. There are significant differences in CA+ (blue striped
bars) compared to individuals without cancer history (CA−, red dotted bars)
between Alzheimer’s disease (AD) diagnostic groups (P = 0.025), including
cognitively normal controls (CN), and individuals with significant memory
concerns (SMC), mild cognitive impairment (MCI), and AD. There is a
smaller percentage of AD CA+, and a larger percentage of SMC CA+,
compared to the CN CA+ percentage, while the MCI CA+/CA− ratio does
not appear to be significantly different than CN CA+/CA−.
Post-hoc analysis examined the largest cancer category, NMSC,
for association with AD diagnostic group. Chi-square analysis
indicated that there were significantly fewer individuals with a
history of NMSC in the AD diagnostic group (10%) compared
to 15% or greater for all other diagnostic groups (χ2 = 16.9,
P = 0.001; Table 4), supporting inclusion of this cancer type in
analyses. Interestingly, no such trend was observed for prostate
cancer (χ2 = 1.8, P = 0.61; Table 4). Breast cancer showed a
trend for fewer individuals in the AD and MCI groups compared
to SMC and CN, but this trend did not reach statistical signifi-
cance (χ2 = 4.8, P = 0.19; Table 4). Other cancer types were not
examined due to insufficient power.
SURVIVAL ANALYSIS OF AGE OF AD ONSET
Kaplan-Meier survival analysis of age of AD onset with cancer his-
tory indicated that those with CA− history had significantly ear-
liermedian age of AD onset, as seen in Figure 3A andTable 5; Cox
regression shows that cancer history is protective against AD, with
CA− 1.5 times more likely to develop AD compared to CA+ (P<
0.001). Importantly, because this analysis was adjusted for APOE
ε4, these results also suggest that cancer history-associated later
age of AD onset is independent of this risk factor. Furthermore,
this effect appears to be additive, as CA+ with one prior cancer
are still 1.3 times more likely to develop AD compared to CA+
with two prior cancers (P < 0.001; Figure 3B, Table 5).
Post-hoc analysis of the two largest cancer categories indicated
that CA+ NMSC showed the cancer protective effect against AD;
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Table 4 | Cancer history by baseline AD diagnostic group.
All cancer types NMSC Prostate cancer Breast cancer
CA+ CA− CA+ CA− CA+ CA− CA+ CA−
CN 129 (33%) 262 (67%) 74 (19%) 317 (81%) 29 (7%) 362 (93%) 19 (5%) 372 (95%)
SMC 34 (44%) 44 (56%) 19 (24%) 59 (76%) 4 (5%) 74 (95%) 5 (6%) 73 (94%)
MCI 257 (31%) 570 (69%) 123 (15%) 704 (85%) 73 (9%) 754 (91%) 25 (3%) 802 (97%)
AD 83 (26%) 230 (74%) 30 (10%) 283 (90%) 24 (8%) 289 (92.3%) 9 (3%) 304 (97%)
Pa 0.025 0.001 0.610 0.190
Values are expressed as count (percentage within diagnostic group). NMSC, non-melanoma skin cancer.
aP-values for Chi-square analyses of each listed cancer type (or all) by diagnostic group.
FIGURE 3 | Survival Analysis of Age of AD onset by Cancer History. (A)
Cox regression of confounder-adjusted age (years) of AD onset for individuals
with (CA+, red line) or without (CA−, blue line) cancer history, indicating that
CA+ have later age of AD onset compared to CA− (P < 0.001). (B) Cox
regression of confounder-adjusted age (years) of AD onset for individuals
with 2 (dark red line), 1 (orange line), or 0 (blue line) prior cancer incidences,
indicating that individuals with 2 prior cancer incidences have later age of AD
onset compared to individuals with 1 or 0 incidences (P < 0.001).
CA− were 1.6 times more likely to develop AD compared to indi-
viduals with a history of NMSC (P < 0.001; Table 5). A similar
protective effect was also observed for prostate cancer, though this
effect was not as significant (P = 0.037; Table 5), possibly due to
the smaller number of individuals with this cancer (see Table 3).
GMD DIFFERENCES BETWEEN GROUPS
As noted above, a linear model of GMD deficits in AD, MCI, and
SMC groups compared to CN was used to confirm that groups
further along the AD spectrum display lower GMD. As expected,
lower GMD was observed for affected groups throughout the
brain, consistent with prior work (Risacher et al., 2009, 2010).
Modeling the opposite relationship, with higher GMD in the AD
group compared to other groups, showed no significant regions
of greater GMD in the AD group. A second VBM analysis exam-
ined all groups irrespective of AD diagnosis, to identify regions
that were increased or decreased in CA+ compared to CA−.
This model showed that CA+ had lower GMD in the right supe-
rior frontal gyrus compared to CA− (peak-level Punc < 0.001,
cluster-level Punc ≤ 0.1; Figure 4A). There were no regions of
significantly greater GMD in CA+ at this threshold. As seen in
Figure 4B, CA+ showed significantly lower GMD in the right
superior frontal gyrus cluster across diagnostic groups.
This finding did not appear to be influenced by disease pro-
gression, as AD individuals did not display any significant differ-
ences compared to CN. Furthermore, comparing CA+ vs. CA−
within each group did not yield any significant regions at this
threshold. A lack of significant cortical and subcortical GMD
differences between CA+/CA− within groups suggests that the
lower CA+ frontal GMD is not being driven by any particular
group, but rather is an underlying difference common to all CA+
in this study cohort.
To further investigate this finding, GMD cluster values were
tested for association with different types of cancer, controlling
for AD diagnostic group and demographic variables. As expected,
GMDwas significantly associated with all cancer types (F = 10.0,
P = 0.002), which was still significant after excluding individu-
als with NMSC (F = 4.9, P = 0.027). GMD was associated with
prostate cancer (F = 4.3, P = 0.039), and showed a trend for
association with breast cancer (F = 3.7, P = 0.055). Interestingly,
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Table 5 | Age of AD onset (AoO) by cancer history.
Method Kaplan-Meier Cox regression
Measure Median AoO 95% CI χ2 P AD OR
All: CA− 81.7 80.7–82.8 20.9 0.000 1.5 1.3–1.8
All: CA+ 84.7 83.4–86.0 *Ref
All: 0 CA− 81.7 80.7–82.8 22.2 0.000 2.0 1.3–3.0
All: 1 CA+ 84.3 83.2–85.4 1.3 0.9–2.1
All: 2 CA+ 85.7 82.4–88.9 Ref
NMSC: CA− 82.4 81.5–83.3 13.3 0.000 1.6 1.2–2.1
NMSC: CA+ 85.7 82.7–88.6 *Ref
Prostate: CA− 82.8 82.0–83.7 4.4 0.037 1.4 1.0–1.8
Prostate: CA+ 84.7 82.6–86.9 Ref
Values for Median AoO and 95% CI are given in years. AoO, age of onset; CI,
confidence interval; AD OR, odds ratio of developing Alzheimer’s disease; *Ref,
reference variable for odds ratio calculation.
GMD only showed a trend for association with NMSC (F = 3.1,
P = 0.081), and showed no association with melanoma (F = 0.0,
P = 0.916).
DISCUSSION
These findings show a significant inverse association between can-
cer and subsequent development of AD in the ADNI cohort, in
concordance with previous epidemiological studies. Importantly,
while previous studies have indicated that this inverse association
is mediated by age, our results are the first to quantify the later age
of AD onset associated with cancer history, as well as to suggest
that this effect may be additive, as the small group of individ-
uals with a history of multiple cancers showed later age of AD
onset compared to individuals with a history of one or no can-
cers. Furthermore, these data demonstrated that NMSC, which
has not been included in most other studies, was a significant
driver of this effect. This suggests that the malignancy of the can-
cer may not be an important factor driving the inverse association
with AD. Alternatively, it may highlight potential environmen-
tal mechanisms, such as sun exposure and subsequent increase
in vitamin D.
In order to obtain a more complete context for this analysis,
cancer history data was compared to U.S. population-level can-
cer data using the SEER Cancer Statistics Review, 1975–2011 data
for cancer incidence and 36-year limited duration prevalence.
SEER data indicates that breast and prostate cancer are the most
common cancer types (with very similar incidence and preva-
lence), followed by colorectal cancer and melanoma. However,
this report did not include NMSC, which would be expected to
have a higher incidence and prevalence (given that squamous
and basal cell carcinomas are largely benign, non-invasive can-
cer types), as observed in the ADNI cancer history data. In ADNI,
history of prostate cancer is more common than breast cancer,
contrary to SEER incidence and first cancer prevalence. This is
perhaps not surprising in this context, as prostate cancer has a
later onset and thus may have a higher prevalence as a second or
third cancer than other cancer types. Additionally, there may be
FIGURE 4 | Lower gray matter density (GMD) with cancer history
across diagnostic groups. (A) Surface rendering shows individuals with a
history of cancer (CA+) display lower GMD than individuals without cancer
history (CA−), across diagnostic groups, in the right superior frontal gyrus
(cluster maximum MNI coordinates 28, 32, 54), shown circled
(Punc < 0.001, cluster threshold Punc ≤ 0.1); this effect is observed to be
bilateral at a more lenient threshold (Punc < 0.01, cluster threshold
Punc ≤ 0.1), shown above. Colored areas indicate regions where CA+ gray
matter density was less than CA− across groups at this threshold; red to
yellow color scale indicates increasing statistical significance, with yellow
areas indicating the most significant regions. (B) GMD values for right
superior frontal gyrus cluster graphed by CA+ (red dotted bars) and CA−
(blue striped bars) across AD diagnostic groups; CA+ have lower GMD
across diagnostic groups.
more prostate cancer in the ADNI sample because there are more
males with cancer participating in this study than females (65%
male CA+). Accounting for these demographic differences, the
cancer history data in the ADNI cohort appears to be relatively
similar to national incidence and prevalence estimates.
There was one notable exception to the correspondence of
ADNI data with the SEER national incidence data. Interestingly,
there was only one reported case of an individual with a prior
incidence of lung cancer in the 1609 individuals included in this
study. This may be due to survival bias; although lung cancer
incidence is quite common (comparable to SEER prostate cancer
age-adjusted incidence in white individuals), lung cancer patients
have very low SEER 5-year survival compared to other types of
cancer (less than 20% for white men and women) (Howlader
et al., 2014).
There are a few other limitations of this study that are impor-
tant to consider. Across diagnostic groups, CA+ individuals were,
on average, older than CA−. This may represent an inherent
study bias; given that CA+ individuals have a later age of AD
onset, older CA+ than CA− would be expected in the AD group.
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However, it is interesting that this trend was also observed in other
diagnostic groups, including CN. One possible explanation may
be that in addition to later age of AD onset, CA+ individuals
also experience later onset of age- or neurodegeneration-related
memory concerns, which may be a motivator to enroll in this
type of study. While this is an important caveat to keep in mind
when interpreting the current results, the Kaplan-Meier survival
analysis method, used to examine age of AD onset with all study
participants, was chosen to minimize this limitation, and as noted
above all neuroimaging analyses covaried for age. There were sev-
eral other demographic differences between CA+/CA− groups;
CA+ had a higher percentage of white non-Hispanic individuals,
likely due to the inclusion of all types of skin cancer in this cate-
gory, and CA+ also had more males, likely due to the prevalence
of prostate cancer in older men, as observed here. Again, all neu-
roimaging analyses covaried for these demographic confounds.
The potential contribution of APOE ε4 to cancer was also consid-
ered; though APOE ε4 alleles are significantly different between
diagnostic groups as noted in the demographics table, individuals
with APOE ε4 alleles were not more likely to have cancer history
than those without at least one APOE ε4 allele, and this factor was
also covaried for in all neuroimaging analyses to account for its
impact on neurodegenerative processes in AD. Age of AD onset
analysis stratifying for APOE ε4 still found CA+ associated with
later age of AD onset, supporting the assertion that APOE ε4
does not appear to be driving the inverse association of cancer
and AD.
The observed lower GMD in CA+ compared to CA− is
not predicted by the common theory of the inverse associa-
tion of cancer and AD, which suggests that CA− would have
lower GMD. However, this finding does fit with studies in can-
cer patients, which have found gray matter reductions in patients
undergoing treatment as well as long-term survivors up to 20
years post-treatment (McDonald et al., 2010, 2013; Koppelmans
et al., 2012b). Additionally, in the present study an increased
percentage of CA+ was observed in the SMC group compared
to other groups, suggesting that while cancer may delay age
of AD onset, CA+ individuals may have increased cognitive
concerns, consistent with the cancer and cognition literature
(Ahles and Saykin, 2007; Mehnert et al., 2007; Weis et al., 2009;
Mandelblatt et al., 2013; McDonald et al., 2013). Interestingly,
the frontal pattern of lower CA+ GMD occurs in regions sim-
ilar to those reported in neuroimaging studies of breast cancer
and chemotherapy-associated gray matter changes (McDonald
et al., 2010, 2013). Sixty-three percent of cancers reported in
ADNI were either NMSC or prostate; chemotherapy is not a
common treatment for either of these, and chemotherapy is
not administered for all patients afflicted with other types of
cancer reported in this study, including breast cancer, the next
most common cancer type. Therefore, while comprehensive treat-
ment data were not available for these patients, it is proba-
ble that the majority did not receive chemotherapy. The CA+
effect observed here could be a synergistic result of cancer-
specific changes in addition to a subgroup of patients experi-
encing chemotherapy treatment-related gray matter effects. The
finding that lower GMD is significantly associated with inva-
sive cancer types, and only showed a trend for association with
NMSC, further supports this idea. These results highlight the
need for more long-term studies of cancer and treatment effects
on neuroimaging measures and cognitive dysfunction, particu-
larly in older patients where these medical factors may predispose
to neurodegeneration or pose an additional risk for cognitive
dysfunction.
Given the finding of lower GMD in CA+, which would be
predicted in the context of cancer and cognition literature but
is unexpected in the context of cancer and neurodegenerative
disease literature, we posit that the inverse association of can-
cer and AD is more complex than the metabolic survival theory
would suggest. As reviewed by Holohan et al. (2012), there are
many potential pathways driving this effect, which may have syn-
ergistic interactions as well. Considering this information, we
propose several alternate biological mechanisms and highlight
important directions for future research of this effect. First, while
baseline imaging indicates lower GMD in CA+ patients, poten-
tially as a long-term result of cancer and related treatments, this
study does not capture the rate at which gray matter is chang-
ing over time in these patients. Examining this data will be an
important step to confirm the neurodegenerative profile of CA+
compared to CA−. Second, analyzing the impact of cancer his-
tory on the amyloid pathway and associated biomarkers may
demonstrate an alternate mechanism through which cancer could
protect against AD. Given that high levels of inflammatory mark-
ers have been associated with poorer survival in cancer, cancer
survivors may be selected for lower cytokine genetic load or
expression, which may be protective against neurotoxic inflam-
mation pathways linked to amyloid plaque accumulation in AD
when compared to unselected individuals with no cancer his-
tory. It is also possible that some polymorphisms in the amyloid
pathway may be inversely associated with cancer and AD; pep-
tidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1) has
been proposed as one such candidate (Balastik et al., 2007;
Driver and Lu, 2010). Finally, a common theory in the cancer
and cognition literature posits that cancer patients and sur-
vivors have gray matter reductions and significantly increased
subjective cognitive concerns, which are not well-correlated with
objective neuropsychological performance, potentially due to
compensatory activation, wherein the brain recruits additional
resources to deal with cognitive challenges. In the ADNI data
there was a higher portion of cancer survivors in the SMC group,
and cancer survivors had lower GMD than CA−; it is possi-
ble that these individuals experience compensatory activation,
similar to that previously shown in a functional MRI study of
breast cancer patients, which may delay cognitive performance
decline and AD diagnosis (McDonald et al., 2012). There are a
multitude of pathways which have been implicated in AD and
cancer, as discussed in Holohan et al. (2012), which require
further functional investigation as well. Future research should
investigate other biomarkers of AD, including longitudinal gray
matter change, amyloid pathway-specific markers, and inflamma-
tory markers, as well as measures of brain activation in cancer
and AD diagnostic groups, to further elucidate the biological
mechanisms underlying the inverse association of cancer and
AD, with the goal of identifying preventative and therapeutic
targets.
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